Jefferies analyst Benjamin Jackson resumed coverage of Genmab (GMAB) with a Buy rating and $41.50 price target The firm says the company’s recent acquisitions have mitigated its terminal value risk. Genmab faces a “catalyst-rich” 2026 which could potentially secure sales growth through the Darzalex royalty decline in 2029, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target
- Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
- Genmab resumed with an Equal Weight at Morgan Stanley
- Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility
- GMAB Upcoming Earnings Report: What to Expect?